AU2007230902B2 - Method to modulate hematopoietic stem cell growth - Google Patents

Method to modulate hematopoietic stem cell growth Download PDF

Info

Publication number
AU2007230902B2
AU2007230902B2 AU2007230902A AU2007230902A AU2007230902B2 AU 2007230902 B2 AU2007230902 B2 AU 2007230902B2 AU 2007230902 A AU2007230902 A AU 2007230902A AU 2007230902 A AU2007230902 A AU 2007230902A AU 2007230902 B2 AU2007230902 B2 AU 2007230902B2
Authority
AU
Australia
Prior art keywords
pge2
hsc
dimethyl
acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007230902A
Other languages
English (en)
Other versions
AU2007230902A8 (en
AU2007230902A1 (en
Inventor
Wolfram Goessling
Trista E. North
Leonard I. Zon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Boston Childrens Hospital
Original Assignee
General Hospital Corp
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Boston Childrens Hospital filed Critical General Hospital Corp
Publication of AU2007230902A1 publication Critical patent/AU2007230902A1/en
Publication of AU2007230902A8 publication Critical patent/AU2007230902A8/en
Assigned to THE GENERAL HOSPITAL CORPORATION, CHILDREN'S MEDICAL CENTER CORPORATION reassignment THE GENERAL HOSPITAL CORPORATION Alteration of Name(s) of Applicant(s) under S113 Assignors: CHILDREN'S MEDICAL CENTER CORPORATION
Application granted granted Critical
Publication of AU2007230902B2 publication Critical patent/AU2007230902B2/en
Priority to AU2013202353A priority Critical patent/AU2013202353B2/en
Priority to AU2015207905A priority patent/AU2015207905B2/en
Priority to AU2017202149A priority patent/AU2017202149B2/en
Priority to AU2019201235A priority patent/AU2019201235B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Materials For Medical Uses (AREA)
AU2007230902A 2006-03-24 2007-03-26 Method to modulate hematopoietic stem cell growth Ceased AU2007230902B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2013202353A AU2013202353B2 (en) 2006-03-24 2013-04-03 Method to modulate hematopoietic stem cell growth
AU2015207905A AU2015207905B2 (en) 2006-03-24 2015-07-30 Method to modulate hematopoietic stem cell growth
AU2017202149A AU2017202149B2 (en) 2006-03-24 2017-03-31 Method to modulate hematopoietic stem cell growth
AU2019201235A AU2019201235B2 (en) 2006-03-24 2019-02-22 Method to modulate hematopoietic stem cell growth

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78596806P 2006-03-24 2006-03-24
US60/785,968 2006-03-24
PCT/US2007/007419 WO2007112084A2 (en) 2006-03-24 2007-03-26 Method to modulate hematopoietic stem cell growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013202353A Division AU2013202353B2 (en) 2006-03-24 2013-04-03 Method to modulate hematopoietic stem cell growth

Publications (3)

Publication Number Publication Date
AU2007230902A1 AU2007230902A1 (en) 2007-10-04
AU2007230902A8 AU2007230902A8 (en) 2009-07-23
AU2007230902B2 true AU2007230902B2 (en) 2013-03-14

Family

ID=38526581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007230902A Ceased AU2007230902B2 (en) 2006-03-24 2007-03-26 Method to modulate hematopoietic stem cell growth

Country Status (10)

Country Link
US (7) US8168428B2 (https=)
EP (3) EP2423303A1 (https=)
JP (8) JP5247675B2 (https=)
CN (2) CN101495623B (https=)
AU (1) AU2007230902B2 (https=)
CA (1) CA2647201C (https=)
MX (3) MX373998B (https=)
RU (2) RU2425876C2 (https=)
WO (1) WO2007112084A2 (https=)
ZA (2) ZA200808123B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
EP3824885A1 (en) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
EP2798956A1 (en) 2007-04-23 2014-11-05 Stowers Institute for Medical Research Methods and compositions for hematopoeitic stem cell self-renewal
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
ITUD20080058A1 (it) 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
US20110206781A1 (en) * 2008-05-28 2011-08-25 Zon Leonard I Method to modulate hematopoietic stem cell growth
CN108379292A (zh) 2008-11-06 2018-08-10 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010108028A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US20120195862A1 (en) * 2009-04-17 2012-08-02 Children's Medical Center Corporation Biomechanical induction of hematopoiesis
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
US11459545B2 (en) 2009-11-15 2022-10-04 Indiana University Research And Technology Corporation Methods to enhance delivery and engraftment of stem cells including the identification of specific prostaglandin E2 receptors
US20130129686A1 (en) * 2009-11-19 2013-05-23 Regents Of The University Reducing Inflammation Using Cell Therapy
JP2013528373A (ja) * 2010-05-10 2013-07-11 フェイト セラピューティクス，インコーポレイテッド 生物学的な用途のための容器
ES2654994T3 (es) * 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas
US10213464B2 (en) * 2011-01-13 2019-02-26 Scipharm Sarl Method for enhancing engraftment of haematopoetic stem cells
EP2701694A4 (en) 2011-04-28 2014-10-08 Univ Duke METHOD FOR THE TREATMENT OF HEMOGLOBINOPATHIES
ES2769270T3 (es) 2011-09-30 2020-06-25 Bluebird Bio Inc Compuestos para transducción viral mejorada
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
WO2013086029A1 (en) 2011-12-05 2013-06-13 Primorigen Biosciences Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
WO2014081760A1 (en) 2012-11-20 2014-05-30 Duke University Methods of treating hemoglobinopathies
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9428748B2 (en) * 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
JP2015205835A (ja) * 2014-04-21 2015-11-19 国立大学法人福井大学 中性子線障害防護剤
CA2946747A1 (en) * 2014-04-23 2015-10-29 Texas Heart Institute Methods of enhancing stem cell engraftment
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
DK3194570T3 (da) 2014-09-16 2021-09-13 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til nukleasemedieret genommodificering og -korrektion i hæmatopoietiske stamceller
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US20180214487A1 (en) 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
CN105296427A (zh) * 2015-10-23 2016-02-03 深圳爱生再生医学科技有限公司 造血干细胞的体外扩增培养方法
US20180338899A1 (en) * 2015-10-30 2018-11-29 Norimasa Miura Inhibitors for methylation-related enzymes hat1 and kat8
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
SG11201803145RA (en) 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
IL261002B2 (en) 2016-02-12 2024-07-01 Bluebird Bio Inc Vcn enhancer compositions and methods of using the same
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
JP2019513010A (ja) * 2016-03-04 2019-05-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー プロスタグランジンｅ２を用いる、筋再生のための組成物および方法
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
EP4520828A3 (en) 2016-11-15 2025-07-09 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
WO2018226797A1 (en) * 2017-06-07 2018-12-13 Academia Sinica Method for removing undifferentiated pluripotent stem cells
WO2018227138A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
EP3672590B1 (en) * 2017-08-22 2025-02-12 The Children's Medical Center Corporation Methods for inducing hematopoietic stem cell specificity
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
EP3597211A1 (en) * 2018-07-19 2020-01-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Periostin compounds for the treatment of haematological complications
CN109609455A (zh) * 2018-12-28 2019-04-12 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
WO2020167948A1 (en) * 2019-02-13 2020-08-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for stem cell therapy
CN110051839A (zh) * 2019-04-16 2019-07-26 诺航生物技术(徐州)有限公司 一种促进脐带血干细胞体外扩增和增强脐带血干细胞移植后造血重建功能的药物
FI130749B1 (en) * 2020-01-24 2024-02-26 Faron Pharmaceuticals Oy USE OF VAP-1 INHIBITOR IN THE EX VIVO CULTURE OF HEMATOPOEITIC STEM CELLS AND IN THE TREATMENT OF BONE Marrow Loss or BONE Marrow Dysfunction
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US11883436B2 (en) 2020-08-17 2024-01-30 The Board Of Trustees Of The University Of Illinois Method of preparing hematopoietic stem and progenitor cells for transplantation
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
KR20240136869A (ko) 2023-03-07 2024-09-19 인제대학교 산학협력단 조혈 줄기세포 증식 또는 가동화 촉진용 조성물 및 가동화 조혈 줄기세포 수집방법
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA103846A (en) 1906-12-03 1907-02-26 William Bell Manufacture of half-tone printing blocks
US3217903A (en) 1961-01-19 1965-11-16 Mc Graw Edison Co Segregating control
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4239679A (en) 1979-06-27 1980-12-16 Diamond Shamrock Corporation High bulk density rigid poly(vinyl chloride) resin powder composition and preparation thereof
HU181154B (en) 1980-07-18 1983-06-28 Epitestudomanyi Intezet Shaped building unit and space limiting or dividing structure made of same as well as method for producing the shaped building unit
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
DK0423980T3 (da) * 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US5114672A (en) 1990-08-27 1992-05-19 Cryo-Cell International, Inc. Method for preserving blood fluid
AU702871B2 (en) * 1993-08-23 1999-03-11 Nexell Therapeutics Inc. (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media
AU6125396A (en) * 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
GB9904281D0 (en) 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
RU2259830C2 (ru) 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
US6226997B1 (en) 1999-12-07 2001-05-08 Cryo-Cell International, Inc. Method and device for maintaining temperature integrity of cryogenically preserved biological samples
US6852534B2 (en) 2000-11-03 2005-02-08 Kourion Therapeutics Gmbh Method to determine an engrafting cell dose of hematopoietic stem cell transplant units
JP4077158B2 (ja) 2001-01-10 2008-04-16 株式会社メニコン 植物性繊維分解剤およびそれを用いた植物性廃棄物の処理法
EP2316919B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7179643B2 (en) 2001-06-14 2007-02-20 Reliance Life Sciences Pvt. Ltd. Device and a process for expansion of haemopoeitic stem cells for therapeutic use
EP1442115B9 (en) 2001-11-15 2009-12-16 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
ATE464373T1 (de) * 2001-12-21 2010-04-15 Mount Sinai Hospital Corp Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
RU2205627C1 (ru) * 2002-05-30 2003-06-10 Открытое акционерное общество "Косметическое объединение "Свобода" Крем для лица, выводящий токсины
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
CA2518193A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
EP1613742A2 (en) 2003-04-08 2006-01-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
GB0324523D0 (en) 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US20080299095A1 (en) * 2004-07-09 2008-12-04 Bc Cancer Agency Nup98-Hox Fusions for Expansion of Hemopoietic Stem Cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
WO2006078886A2 (en) 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
EP1859028B1 (en) 2005-02-10 2015-12-02 Regents Of The University Of Minnesota Vascular endothelial cells
WO2007117262A2 (en) 2005-07-29 2007-10-18 Athersys, Inc. Culture of non-embryonic cells at high cell density
JP4562618B2 (ja) 2005-08-18 2010-10-13 陽一 佐藤 空き缶処理車
AU2006326853B2 (en) * 2005-12-22 2012-02-16 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
WO2007148332A1 (en) 2006-06-22 2007-12-27 Yeda Resaerch And Development Co. Ltd Catecholamine receptor modulation
US20100233135A1 (en) 2006-08-16 2010-09-16 The General Hospital Corporation Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis
WO2008056963A1 (en) 2006-11-10 2008-05-15 Chanil Moon Method for proliferating stem cells with leptin
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Feher, I et al., Nature, 1974, Vol.247, pages 550-551 *

Also Published As

Publication number Publication date
WO2007112084A8 (en) 2008-11-20
RU2425876C2 (ru) 2011-08-10
AU2007230902A8 (en) 2009-07-23
MX2019007494A (es) 2019-09-06
JP6797222B2 (ja) 2020-12-09
JP2009530408A (ja) 2009-08-27
CN101495623B (zh) 2013-09-11
US20120189594A1 (en) 2012-07-26
US20120189592A1 (en) 2012-07-26
JP6041711B2 (ja) 2016-12-14
US20130209424A1 (en) 2013-08-15
JP2015232010A (ja) 2015-12-24
EP2423303A1 (en) 2012-02-29
AU2007230902A1 (en) 2007-10-04
CA2647201A1 (en) 2007-10-04
JP2022025091A (ja) 2022-02-09
MX2008012178A (es) 2009-01-23
CN101495623A (zh) 2009-07-29
EP3424507A1 (en) 2019-01-09
JP2019094347A (ja) 2019-06-20
US9028811B2 (en) 2015-05-12
US8168428B2 (en) 2012-05-01
CN102626517B (zh) 2015-07-29
JP6208719B2 (ja) 2017-10-04
MX373998B (es) 2020-07-22
US10272110B2 (en) 2019-04-30
JP2013155175A (ja) 2013-08-15
JP6530732B2 (ja) 2019-06-12
JP5247675B2 (ja) 2013-07-24
WO2007112084A9 (en) 2007-11-22
HK1173948A1 (en) 2013-05-31
JP2019214620A (ja) 2019-12-19
US8563310B2 (en) 2013-10-22
US20130216507A1 (en) 2013-08-22
US20090285786A1 (en) 2009-11-19
CN102626517A (zh) 2012-08-08
WO2007112084A2 (en) 2007-10-04
WO2007112084A3 (en) 2009-01-08
JP2023112027A (ja) 2023-08-10
RU2493252C2 (ru) 2013-09-20
US20120189593A1 (en) 2012-07-26
US20130209423A1 (en) 2013-08-15
ZA200906574B (en) 2010-06-30
RU2011115827A (ru) 2012-10-27
CA2647201C (en) 2016-03-08
US8551782B2 (en) 2013-10-08
US10278990B2 (en) 2019-05-07
ZA200808123B (en) 2010-03-31
EP1999255A2 (en) 2008-12-10
RU2008142106A (ru) 2010-04-27
JP2016210802A (ja) 2016-12-15

Similar Documents

Publication Publication Date Title
AU2007230902B2 (en) Method to modulate hematopoietic stem cell growth
AU2019201235B2 (en) Method to modulate hematopoietic stem cell growth
AU2013202353B2 (en) Method to modulate hematopoietic stem cell growth
HK40002933A (en) Method to modulate hematopoietic stem cell growth
HK1164363A (en) Method to modulate hematopoietic stem cell growth

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 22, NO 41, PAGE(S) 4858 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME CHILDREN'S MEDICAL CENTER CORPORATION, APPLICATION NO. 2007230902, UNDER INID(22) AMEND THE DATE TO READ 26 MAR 2007

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GOESSLING, WOLFRAM; ZON, LEONARD I. AND NORTH, TRISTA E. .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GOESSLING, WOLFRAM; ZON, LEONARD I. AND NORTH, TRISTA E.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired